Lax I - Search Results

1

FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho.

Suzuki Y, Kuzina E, An SJ, Tome F, Mohanty J, Li W, Lee S, Liu Y, Lax I, Schlessinger J. Suzuki Y, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31800-31807. doi: 10.1073/pnas.2018554117. Epub 2020 Nov 30. Proc Natl Acad Sci U S A. 2020. PMID: 33257569 Free PMC article.

2

Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses.

Spivak-Kroizman T, Rotin D, Pinchasi D, Ullrich A, Schlessinger J, Lax I. Spivak-Kroizman T, et al. Among authors: lax i. J Biol Chem. 1992 Apr 25;267(12):8056-63. J Biol Chem. 1992. PMID: 1349015 Free article.

3

Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain.

Lax I, Mitra AK, Ravera C, Hurwitz DR, Rubinstein M, Ullrich A, Stroud RM, Schlessinger J. Lax I, et al. J Biol Chem. 1991 Jul 25;266(21):13828-33. J Biol Chem. 1991. PMID: 1856216 Free article.

4

Domain deletion in the extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression.

Lax I, Bellot F, Honegger AM, Schmidt A, Ullrich A, Givol D, Schlessinger J. Lax I, et al. Cell Regul. 1990 Jan;1(2):173-88. doi: 10.1091/mbc.1.2.173. Cell Regul. 1990. PMID: 2100196 Free PMC article.

5

HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor.

Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A. Lee J, et al. Among authors: lax i. EMBO J. 1989 Jan;8(1):167-73. doi: 10.1002/j.1460-2075.1989.tb03361.x. EMBO J. 1989. PMID: 2565808 Free PMC article.

6

Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling.

Lax I, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Lax I, et al. Mol Cell Biol. 1988 Apr;8(4):1831-4. doi: 10.1128/mcb.8.4.1831-1834.1988. Mol Cell Biol. 1988. PMID: 3260004 Free PMC article.

7

Monoclonal antibodies against epidermal growth factor receptor induce prolactin synthesis in cultured rat pituitary cells (GH3).

Hapgood J, Libermann TA, Lax I, Yarden Y, Schreiber AB, Naor Z, Schlessinger J. Hapgood J, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 1983 Nov;80(21):6451-5. doi: 10.1073/pnas.80.21.6451. Proc Natl Acad Sci U S A. 1983. PMID: 6195656 Free PMC article.

8

Antibodies to two defined regions of the transforming protein pp60src interact specifically with the epidermal growth factor receptor kinase system.

Lax I, Bar-Eli M, Yarden Y, Libermann TA, Schlessinger J. Lax I, et al. Proc Natl Acad Sci U S A. 1984 Oct;81(19):5911-5. doi: 10.1073/pnas.81.19.5911. Proc Natl Acad Sci U S A. 1984. PMID: 6207534 Free PMC article.

9

Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.

Schreiber AB, Lax I, Yarden Y, Eshhar Z, Schlessinger J. Schreiber AB, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7535-9. doi: 10.1073/pnas.78.12.7535. Proc Natl Acad Sci U S A. 1981. PMID: 6278478 Free PMC article.

10

Point mutation in the fibroblast growth factor receptor eliminates phosphatidylinositol hydrolysis without affecting neuronal differentiation of PC12 cells.

Spivak-Kroizman T, Mohammadi M, Hu P, Jaye M, Schlessinger J, Lax I. Spivak-Kroizman T, et al. Among authors: lax i. J Biol Chem. 1994 May 20;269(20):14419-23. J Biol Chem. 1994. PMID: 7514169 Free article.

11

Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation.

Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Spivak-Kroizman T, et al. Among authors: lax i. Cell. 1994 Dec 16;79(6):1015-24. doi: 10.1016/0092-8674(94)90032-9. Cell. 1994. PMID: 7528103

12

PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation.

Dikic I, Schlessinger J, Lax I. Dikic I, et al. Among authors: lax i. Curr Biol. 1994 Aug 1;4(8):702-8. doi: 10.1016/s0960-9822(00)00155-x. Curr Biol. 1994. PMID: 7953556

13

Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation.

Zhou M, Felder S, Rubinstein M, Hurwitz DR, Ullrich A, Lax I, Schlessinger J. Zhou M, et al. Among authors: lax i. Biochemistry. 1993 Aug 17;32(32):8193-8. doi: 10.1021/bi00083a020. Biochemistry. 1993. PMID: 8347619

14

Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?

Schlessinger J, Lax I, Lemmon M. Schlessinger J, et al. Among authors: lax i. Cell. 1995 Nov 3;83(3):357-60. doi: 10.1016/0092-8674(95)90112-4. Cell. 1995. PMID: 8521464 Free article. Review. No abstract available.

15

Two EGF molecules contribute additively to stabilization of the EGFR dimer.

Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, Schlessinger J. Lemmon MA, et al. Among authors: lax i. EMBO J. 1997 Jan 15;16(2):281-94. doi: 10.1093/emboj/16.2.281. EMBO J. 1997. PMID: 9029149 Free PMC article.

16

Kit receptor dimerization is driven by bivalent binding of stem cell factor.

Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J. Lemmon MA, et al. Among authors: lax i. J Biol Chem. 1997 Mar 7;272(10):6311-7. doi: 10.1074/jbc.272.10.6311. J Biol Chem. 1997. PMID: 9045650 Free article.

17

A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.

Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J. Kouhara H, et al. Among authors: lax i. Cell. 1997 May 30;89(5):693-702. doi: 10.1016/s0092-8674(00)80252-4. Cell. 1997. PMID: 9182757 Free article.

18

Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor.

Odaka M, Kohda D, Lax I, Schlessinger J, Inagaki F. Odaka M, et al. Among authors: lax i. J Biochem. 1997 Jul;122(1):116-21. doi: 10.1093/oxfordjournals.jbchem.a021718. J Biochem. 1997. PMID: 9276679 Free article.

19

Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation.

Hadari YR, Kouhara H, Lax I, Schlessinger J. Hadari YR, et al. Among authors: lax i. Mol Cell Biol. 1998 Jul;18(7):3966-73. doi: 10.1128/MCB.18.7.3966. Mol Cell Biol. 1998. PMID: 9632781 Free PMC article.

20

Structure of a heparin-linked biologically active dimer of fibroblast growth factor.

DiGabriele AD, Lax I, Chen DI, Svahn CM, Jaye M, Schlessinger J, Hendrickson WA. DiGabriele AD, et al. Among authors: lax i. Nature. 1998 Jun 25;393(6687):812-7. doi: 10.1038/31741. Nature. 1998. PMID: 9655399

21

Nerve growth factor acutely reduces chemical transmission by means of postsynaptic TrkA-like receptors in squid giant synapse.

Moreno H, Nadal M, Leznik E, Sugimori M, Lax I, Schlessinger J, Llinás R. Moreno H, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14997-5002. doi: 10.1073/pnas.95.25.14997. Proc Natl Acad Sci U S A. 1998. PMID: 9844004 Free PMC article.

22

FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.

Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J, Lax I. Ong SH, et al. Among authors: lax i. Mol Cell Biol. 2000 Feb;20(3):979-89. doi: 10.1128/MCB.20.3.979-989.2000. Mol Cell Biol. 2000. PMID: 10629055 Free PMC article.

23

Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.

Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Ong SH, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6074-9. doi: 10.1073/pnas.111114298. Epub 2001 May 15. Proc Natl Acad Sci U S A. 2001. PMID: 11353842 Free PMC article.

24

Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.

Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. Hadari YR, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8578-83. doi: 10.1073/pnas.161259898. Epub 2001 Jul 10. Proc Natl Acad Sci U S A. 2001. PMID: 11447289 Free PMC article.

25

FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl.

Wong A, Lamothe B, Lee A, Schlessinger J, Lax I. Wong A, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2002 May 14;99(10):6684-9. doi: 10.1073/pnas.052138899. Epub 2002 May 7. Proc Natl Acad Sci U S A. 2002. PMID: 11997436 Free PMC article.

26

The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors.

Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J. Lax I, et al. Mol Cell. 2002 Oct;10(4):709-19. doi: 10.1016/s1097-2765(02)00689-5. Mol Cell. 2002. PMID: 12419216 Free article.

27

The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function.

Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. Mattoon D, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):923-8. doi: 10.1073/pnas.0307286101. Epub 2004 Jan 19. Proc Natl Acad Sci U S A. 2004. PMID: 14732693 Free PMC article.

28

FRS2 family docking proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal patterns of expression of their transcripts.

Gotoh N, Laks S, Nakashima M, Lax I, Schlessinger J. Gotoh N, et al. Among authors: lax i. FEBS Lett. 2004 Apr 23;564(1-2):14-8. doi: 10.1016/S0014-5793(04)00287-X. FEBS Lett. 2004. PMID: 15094036 Free article.

29

The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway.

Lamothe B, Yamada M, Schaeper U, Birchmeier W, Lax I, Schlessinger J. Lamothe B, et al. Among authors: lax i. Mol Cell Biol. 2004 Jul;24(13):5657-66. doi: 10.1128/MCB.24.13.5657-5666.2004. Mol Cell Biol. 2004. PMID: 15199124 Free PMC article.

30

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway.

Mattoon DR, Lamothe B, Lax I, Schlessinger J. Mattoon DR, et al. Among authors: lax i. BMC Biol. 2004 Nov 18;2:24. doi: 10.1186/1741-7007-2-24. BMC Biol. 2004. PMID: 15550174 Free PMC article.

31

Tyrosine phosphorylation sites on FRS2alpha responsible for Shp2 recruitment are critical for induction of lens and retina.

Gotoh N, Ito M, Yamamoto S, Yoshino I, Song N, Wang Y, Lax I, Schlessinger J, Shibuya M, Lang RA. Gotoh N, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17144-9. doi: 10.1073/pnas.0407577101. Epub 2004 Nov 29. Proc Natl Acad Sci U S A. 2004. PMID: 15569927 Free PMC article.

32

Cellular signaling by fibroblast growth factor receptors.

Eswarakumar VP, Lax I, Schlessinger J. Eswarakumar VP, et al. Among authors: lax i. Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49. doi: 10.1016/j.cytogfr.2005.01.001. Epub 2005 Feb 1. Cytokine Growth Factor Rev. 2005. PMID: 15863030 Review.

33

The docking protein FRS2alpha is an essential component of multiple fibroblast growth factor responses during early mouse development.

Gotoh N, Manova K, Tanaka S, Murohashi M, Hadari Y, Lee A, Hamada Y, Hiroe T, Ito M, Kurihara T, Nakazato H, Shibuya M, Lax I, Lacy E, Schlessinger J. Gotoh N, et al. Among authors: lax i. Mol Cell Biol. 2005 May;25(10):4105-16. doi: 10.1128/MCB.25.10.4105-4116.2005. Mol Cell Biol. 2005. PMID: 15870281 Free PMC article.

34

Essential role of Shp2-binding sites on FRS2alpha for corticogenesis and for FGF2-dependent proliferation of neural progenitor cells.

Yamamoto S, Yoshino I, Shimazaki T, Murohashi M, Hevner RF, Lax I, Okano H, Shibuya M, Schlessinger J, Gotoh N. Yamamoto S, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15983-8. doi: 10.1073/pnas.0507961102. Epub 2005 Oct 20. Proc Natl Acad Sci U S A. 2005. PMID: 16239343 Free PMC article.

35

On the nature of low- and high-affinity EGF receptors on living cells.

Ozcan F, Klein P, Lemmon MA, Lax I, Schlessinger J. Ozcan F, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5735-40. doi: 10.1073/pnas.0601469103. Epub 2006 Mar 29. Proc Natl Acad Sci U S A. 2006. PMID: 16571657 Free PMC article.

36

Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis.

Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tomé F, Booth CJ, Adams DJ, Lax I, Schlessinger J. Eswarakumar VP, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18603-8. doi: 10.1073/pnas.0609157103. Epub 2006 Nov 28. Proc Natl Acad Sci U S A. 2006. PMID: 17132737 Free PMC article.

37

Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.

Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Yuzawa S, et al. Among authors: lax i. Cell. 2007 Jul 27;130(2):323-34. doi: 10.1016/j.cell.2007.05.055. Cell. 2007. PMID: 17662946 Free article.

38

Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway.

Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J, Lax I. Shams I, et al. Among authors: lax i. Mol Cell Biol. 2007 Oct;27(19):6903-12. doi: 10.1128/MCB.00544-07. Epub 2007 Aug 6. Mol Cell Biol. 2007. PMID: 17682060 Free PMC article.

39

Surface binding inhibitors of the SCF-KIT protein-protein interaction.

Margulies D, Opatowsky Y, Fletcher S, Saraogi I, Tsou LK, Saha S, Lax I, Schlessinger J, Hamilton AD. Margulies D, et al. Among authors: lax i. Chembiochem. 2009 Aug 17;10(12):1955-8. doi: 10.1002/cbic.200900079. Chembiochem. 2009. PMID: 19637142 Free PMC article. No abstract available.

40

The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.

Bae JH, Lew ED, Yuzawa S, Tomé F, Lax I, Schlessinger J. Bae JH, et al. Among authors: lax i. Cell. 2009 Aug 7;138(3):514-24. doi: 10.1016/j.cell.2009.05.028. Cell. 2009. PMID: 19665973 Free PMC article.

41

Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.

Bae JH, Boggon TJ, Tomé F, Mandiyan V, Lax I, Schlessinger J. Bae JH, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2866-71. doi: 10.1073/pnas.0914157107. Epub 2010 Jan 26. Proc Natl Acad Sci U S A. 2010. PMID: 20133753 Free PMC article.

42

FRS2α regulates Erk levels to control a self-renewal target Hes1 and proliferation of FGF-responsive neural stem/progenitor cells.

Sato T, Shimazaki T, Naka H, Fukami S, Satoh Y, Okano H, Lax I, Schlessinger J, Gotoh N. Sato T, et al. Among authors: lax i. Stem Cells. 2010 Sep;28(9):1661-73. doi: 10.1002/stem.488. Stem Cells. 2010. PMID: 20652960 Free PMC article.

43

Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane.

Sousa LP, Lax I, Shen H, Ferguson SM, De Camilli P, Schlessinger J. Sousa LP, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4419-24. doi: 10.1073/pnas.1200164109. Epub 2012 Feb 27. Proc Natl Acad Sci U S A. 2012. PMID: 22371560 Free PMC article.

44

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.

Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J. Reshetnyak AV, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17832-7. doi: 10.1073/pnas.1317118110. Epub 2013 Oct 14. Proc Natl Acad Sci U S A. 2013. PMID: 24127596 Free PMC article.

45

Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.

Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J. Opatowsky Y, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1772-7. doi: 10.1073/pnas.1323254111. Epub 2014 Jan 21. Proc Natl Acad Sci U S A. 2014. PMID: 24449920 Free PMC article.

46

The docking protein FRS2α is a critical regulator of VEGF receptors signaling.

Chen PY, Qin L, Zhuang ZW, Tellides G, Lax I, Schlessinger J, Simons M. Chen PY, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5514-9. doi: 10.1073/pnas.1404545111. Epub 2014 Apr 2. Proc Natl Acad Sci U S A. 2014. PMID: 24706887 Free PMC article.

47

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.

Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G. Lew ED, et al. Among authors: lax i. Elife. 2014 Sep 29;3:e03385. doi: 10.7554/eLife.03385. Elife. 2014. PMID: 25265470 Free PMC article.

48

The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.

Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J. Reshetnyak AV, et al. Among authors: lax i. Mol Cell. 2015 Jan 8;57(1):191-201. doi: 10.1016/j.molcel.2014.11.021. Epub 2014 Dec 24. Mol Cell. 2015. PMID: 25544564 Free PMC article.

49

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J. Murray PB, et al. Among authors: lax i. Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916. Sci Signal. 2015. PMID: 25605972

50

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.

Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J. Reshetnyak AV, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7. doi: 10.1073/pnas.1520099112. Epub 2015 Nov 16. Proc Natl Acad Sci U S A. 2015. PMID: 26630010 Free PMC article.

51

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.

Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I. Shi X, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4784-93. doi: 10.1073/pnas.1610179113. Epub 2016 Aug 1. Proc Natl Acad Sci U S A. 2016. PMID: 27482095 Free PMC article.

52

Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.

Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J. Lee S, et al. Among authors: lax i. Nature. 2018 Jan 25;553(7689):501-505. doi: 10.1038/nature25010. Epub 2018 Jan 17. Nature. 2018. PMID: 29342135 Free PMC article.

53

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J. Reshetnyak AV, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30. Proc Natl Acad Sci U S A. 2018. PMID: 30061385 Free PMC article.

54

Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.

Kuzina ES, Ung PM, Mohanty J, Tome F, Choi J, Pardon E, Steyaert J, Lax I, Schlessinger A, Schlessinger J, Lee S. Kuzina ES, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7819-7824. doi: 10.1073/pnas.1822055116. Epub 2019 Apr 3. Proc Natl Acad Sci U S A. 2019. PMID: 30944224 Free PMC article.

55

Structural basis for ligand reception by anaplastic lymphoma kinase.

Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE. Li T, et al. Among authors: lax i. Nature. 2021 Dec;600(7887):148-152. doi: 10.1038/s41586-021-04141-7. Epub 2021 Nov 24. Nature. 2021. PMID: 34819665 Free PMC article.

56

Mechanism for the activation of the anaplastic lymphoma kinase receptor.

Reshetnyak AV, Rossi P, Myasnikov AG, Sowaileh M, Mohanty J, Nourse A, Miller DJ, Lax I, Schlessinger J, Kalodimos CG. Reshetnyak AV, et al. Among authors: lax i. Nature. 2021 Dec;600(7887):153-157. doi: 10.1038/s41586-021-04140-8. Epub 2021 Nov 24. Nature. 2021. PMID: 34819673 Free PMC article.

57

Heparin is essential for optimal cell signaling by FGF21 and for regulation of βKlotho cellular stability.

An SJ, Mohanty J, Tome F, Suzuki Y, Lax I, Schlessinger J. An SJ, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2219128120. doi: 10.1073/pnas.2219128120. Epub 2023 Feb 6. Proc Natl Acad Sci U S A. 2023. PMID: 36745784 Free PMC article.

58

Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention.

Krimmer SG, Bertoletti N, Suzuki Y, Katic L, Mohanty J, Shu S, Lee S, Lax I, Mi W, Schlessinger J. Krimmer SG, et al. Among authors: lax i. Proc Natl Acad Sci U S A. 2023 Mar 28;120(13):e2300054120. doi: 10.1073/pnas.2300054120. Epub 2023 Mar 21. Proc Natl Acad Sci U S A. 2023. PMID: 36943885 Free PMC article.

59

EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain.

Hurwitz DR, Emanuel SL, Nathan MH, Sarver N, Ullrich A, Felder S, Lax I, Schlessinger J. Hurwitz DR, et al. Among authors: lax i. J Biol Chem. 1991 Nov 15;266(32):22035-43. J Biol Chem. 1991. PMID: 1657987 Free article.

60

Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity.

Lax I, Fischer R, Ng C, Segre J, Ullrich A, Givol D, Schlessinger J. Lax I, et al. Cell Regul. 1991 May;2(5):337-45. doi: 10.1091/mbc.2.5.337. Cell Regul. 1991. PMID: 1716463 Free PMC article.

61

Comparison of EGF receptor sequences as a guide to study the ligand binding site.

Avivi A, Lax I, Ullrich A, Schlessinger J, Givol D, Morse B. Avivi A, et al. Among authors: lax i. Oncogene. 1991 Apr;6(4):673-6. Oncogene. 1991. PMID: 2030916

62

All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.

Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, Schlessinger J. Margolis BL, et al. Among authors: lax i. J Biol Chem. 1989 Jun 25;264(18):10667-71. J Biol Chem. 1989. PMID: 2543678 Free article.

63

Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules.

Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Lax I, et al. EMBO J. 1989 Feb;8(2):421-7. doi: 10.1002/j.1460-2075.1989.tb03393.x. EMBO J. 1989. PMID: 2785915 Free PMC article.

64

Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies.

Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J. Schreiber AB, et al. Among authors: lax i. J Biol Chem. 1983 Jan 25;258(2):846-53. J Biol Chem. 1983. PMID: 6296087 Free article.

The specificity of the antibodies was established by immunoprecipitation of the receptor from biosynthetically labeled cells. The previously described (Schreiber, A. B., Lax, I., Yarden, Y., Eshhar, Z., and Schlessinger, J. (1981) Proc. ...

The specificity of the antibodies was established by immunoprecipitation of the receptor from biosynthetically labeled cells. The previously …

65

Regulation of cell proliferation by epidermal growth factor.

Schlessinger J, Schreiber AB, Levi A, Lax I, Libermann T, Yarden Y. Schlessinger J, et al. Among authors: lax i. CRC Crit Rev Biochem. 1983;14(2):93-111. doi: 10.3109/10409238309102791. CRC Crit Rev Biochem. 1983. PMID: 6301752 Review.

66

A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor.

Kohda D, Odaka M, Lax I, Kawasaki H, Suzuki K, Ullrich A, Schlessinger J, Inagaki F. Kohda D, et al. Among authors: lax i. J Biol Chem. 1993 Jan 25;268(3):1976-81. J Biol Chem. 1993. PMID: 8420971 Free article.

67

Disulfide bond structure of human epidermal growth factor receptor.

Abe Y, Odaka M, Inagaki F, Lax I, Schlessinger J, Kohda D. Abe Y, et al. Among authors: lax i. J Biol Chem. 1998 May 1;273(18):11150-7. doi: 10.1074/jbc.273.18.11150. J Biol Chem. 1998. PMID: 9556602 Free article.

68

Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor.

Domagala T, Konstantopoulos N, Smyth F, Jorissen RN, Fabri L, Geleick D, Lax I, Schlessinger J, Sawyer W, Howlett GJ, Burgess AW, Nice EC. Domagala T, et al. Among authors: lax i. Growth Factors. 2000;18(1):11-29. doi: 10.3109/08977190009003231. Growth Factors. 2000. PMID: 10831070

69

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I. Melillo RM, et al. Among authors: lax i. Mol Cell Biol. 2001 Jul;21(13):4177-87. doi: 10.1128/MCB.21.13.4177-4187.2001. Mol Cell Biol. 2001. PMID: 11390647 Free PMC article.

70

Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbB protein.

Kris RM, Lax I, Gullick W, Waterfield MD, Ullrich A, Fridkin M, Schlessinger J. Kris RM, et al. Among authors: lax i. Cell. 1985 Mar;40(3):619-25. doi: 10.1016/0092-8674(85)90210-7. Cell. 1985. PMID: 2982501

71

Synthetic peptide approach to the analysis of kinase activities of avian EGF receptor and v-erbB protein.

Kris RM, Lax I, Sasson I, Copf B, Werlin S, Gullick W, Waterfield MD, Ullrich A, Fridkin M, Schlessinger J. Kris RM, et al. Among authors: lax i. Biochimie. 1985 Oct-Nov;67(10-11):1095-101. doi: 10.1016/s0300-9084(85)80106-1. Biochimie. 1985. PMID: 3000459

72

Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha.

Lax I, Johnson A, Howk R, Sap J, Bellot F, Winkler M, Ullrich A, Vennstrom B, Schlessinger J, Givol D. Lax I, et al. Mol Cell Biol. 1988 May;8(5):1970-8. doi: 10.1128/mcb.8.5.1970-1978.1988. Mol Cell Biol. 1988. PMID: 3260329 Free PMC article.

73

Induction of cell attachment and morphological differentiation in a pheochromocytoma cell line and embryonal sensory cells by the extracellular matrix.

Vlodavsky I, Levi A, Lax I, Fuks Z, Schlessinger J. Vlodavsky I, et al. Among authors: lax i. Dev Biol. 1982 Oct;93(2):285-300. doi: 10.1016/0012-1606(82)90118-x. Dev Biol. 1982. PMID: 7141098 No abstract available.

74

Activation of c-erbB in avian leukosis virus-induced erythroblastosis leads to the expression of a truncated EGF receptor kinase.

Lax I, Kris R, Sasson I, Ullrich A, Hayman MJ, Beug H, Schlessinger J. Lax I, et al. EMBO J. 1985 Dec 1;4(12):3179-82. doi: 10.1002/j.1460-2075.1985.tb04062.x. EMBO J. 1985. PMID: 3004938 Free PMC article.

75

Monoclonal antibody reactive with the human epidermal-growth-factor receptor recognizes the blood-group-A antigen.

Gooi HC, Schlessinger J, Lax I, Yarden Y, Libermann TA, Feizi T. Gooi HC, et al. Among authors: lax i. Biosci Rep. 1983 Nov;3(11):1045-52. doi: 10.1007/BF01121031. Biosci Rep. 1983. PMID: 6198005

76

Amplification and overexpression of the EGF receptor gene in primary human glioblastomas.

Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Libermann TA, et al. Among authors: lax i. J Cell Sci Suppl. 1985;3:161-72. doi: 10.1242/jcs.1985.supplement_3.16. J Cell Sci Suppl. 1985. PMID: 3011820

77

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Libermann TA, et al. Among authors: lax i. Nature. 1985 Jan 10-18;313(5998):144-7. doi: 10.1038/313144a0. Nature. 1985. PMID: 2981413

78

Molecular steps in the action and regulation of epidermal growth factor: a cellular mitogen.

Schlessinger J, Schreiber AB, Lax I, Yashuv-Gan Y, Libermann TA, Hillman GM, Levi A, Yarden Y. Schlessinger J, et al. Among authors: lax i. Prog Clin Biol Res. 1982;91:359-72. Prog Clin Biol Res. 1982. PMID: 6292947 No abstract available.

79

The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells.

Gooi HC, Hounsell EF, Lax I, Kris RM, Libermann TA, Schlessinger J, Sato JD, Kawamoto T, Mendelsohn J, Feizi T. Gooi HC, et al. Among authors: lax i. Biosci Rep. 1985 Jan;5(1):83-94. doi: 10.1007/BF01117444. Biosci Rep. 1985. PMID: 2580573

80

Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.

Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R, Lindberg K. Lindberg S, et al. Among authors: lax i. Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1222-1231. doi: 10.1016/j.ijrobp.2023.06.246. Epub 2023 Jul 8. Int J Radiat Oncol Biol Phys. 2023. PMID: 37423292

81

Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects.

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Friesland S. Embring A, et al. Among authors: lax i. Cancers (Basel). 2023 Apr 30;15(9):2580. doi: 10.3390/cancers15092580. Cancers (Basel). 2023. PMID: 37174046 Free PMC article.

82

Radiotherapy-Dose Escalated for Large Volume Primary Tumors-And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck-A Randomized Phase II Trial.

Mercke C, Wickart-Johansson G, Sjödin H, Farrajota Neves da Silva P, Alexandersson von Döbeln G, Margolin G, Jonmarker Jaraj S, Carstens H, Berglund A, Lax I, Hellström M, Hammarstedt-Nordenvall L, Friesland S. Mercke C, et al. Among authors: lax i. Cancers (Basel). 2023 Apr 28;15(9):2543. doi: 10.3390/cancers15092543. Cancers (Basel). 2023. PMID: 37174008 Free PMC article.

83

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost.

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Friesland S. Embring A, et al. Among authors: lax i. Radiat Oncol. 2023 Apr 7;18(1):65. doi: 10.1186/s13014-023-02256-x. Radiat Oncol. 2023. PMID: 37029424 Free PMC article.

84

Risk for Hemorrhage the First 2 Years After Gamma Knife Surgery for Arteriovenous Malformations: An Update.

Karlsson B, Jokura H, Yang HC, Yamamoto M, Martinez-Alvarez R, Kawagishi J, Guo WY, Chung WY, Söderman M, Yeo TT, Lax I. Karlsson B, et al. Among authors: lax i. Neurosurgery. 2022 Dec 1;91(6):920-927. doi: 10.1227/neu.0000000000002130. Epub 2022 Oct 5. Neurosurgery. 2022. PMID: 36219806 Free PMC article.

85

In Response to Rosenberg et al. "The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window".

Lindberg K, Lax I, Karlsson K, Lewensohn R. Lindberg K, et al. Among authors: lax i. J Thorac Oncol. 2021 Oct;16(10):e81-e82. doi: 10.1016/j.jtho.2021.08.005. J Thorac Oncol. 2021. PMID: 34561040 Free article. No abstract available.

86

Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects.

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Bornedal S, Wennberg B, Dalqvist E, Friesland S. Embring A, et al. Among authors: lax i. Cancers (Basel). 2021 Jun 25;13(13):3173. doi: 10.3390/cancers13133173. Cancers (Basel). 2021. PMID: 34202135 Free PMC article.

87

Estimation of delivered dose to lung tumours considering setup uncertainties and breathing motion in a cohort of patients treated with stereotactic body radiation therapy.

Karlsson K, Lax I, Lindbäck E, Grozman V, Lindberg K, Wersäll P, Poludniowski G. Karlsson K, et al. Among authors: lax i. Phys Med. 2021 Aug;88:53-64. doi: 10.1016/j.ejmp.2021.06.015. Epub 2021 Jun 25. Phys Med. 2021. PMID: 34175747

88

The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.

Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R. Lindberg K, et al. Among authors: lax i. J Thorac Oncol. 2021 Jul;16(7):1200-1210. doi: 10.1016/j.jtho.2021.03.019. Epub 2021 Apr 3. J Thorac Oncol. 2021. PMID: 33823286 Free article. Clinical Trial.

89

Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects.

Grozman V, Onjukka E, Wersäll P, Lax I, Tsakonas G, Nyren S, Lewensohn R, Lindberg K. Grozman V, et al. Among authors: lax i. Acta Oncol. 2021 Mar;60(3):305-311. doi: 10.1080/0284186X.2020.1866776. Epub 2021 Jan 15. Acta Oncol. 2021. PMID: 33448899

90

Modeling of Xerostomia After Radiotherapy for Head and Neck Cancer: A Registry Study.

Onjukka E, Mercke C, Björgvinsson E, Embring A, Berglund A, Alexandersson von Döbeln G, Friesland S, Gagliardi G, Lenneby Helleday C, Sjödin H, Lax I. Onjukka E, et al. Among authors: lax i. Front Oncol. 2020 Aug 14;10:1647. doi: 10.3389/fonc.2020.01647. eCollection 2020. Front Oncol. 2020. PMID: 32923404 Free PMC article.

91

Overlapping volumes in re-irradiation for head and neck cancer - an important factor for patient selection.

Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Bornedal S, Wennberg B, Friesland S. Embring A, et al. Among authors: lax i. Radiat Oncol. 2020 Jun 8;15(1):147. doi: 10.1186/s13014-020-01587-3. Radiat Oncol. 2020. PMID: 32513217 Free PMC article.

92

Cytokinin treatment modifies litchi fruit pericarp anatomy leading to reduced susceptibility to post-harvest pericarp browning.

Fahima A, Levinkron S, Maytal Y, Hugger A, Lax I, Huang X, Eyal Y, Lichter A, Goren M, Stern RA, Harpaz-Saad S. Fahima A, et al. Among authors: lax i. Plant Sci. 2019 Jun;283:41-50. doi: 10.1016/j.plantsci.2019.02.006. Epub 2019 Feb 13. Plant Sci. 2019. PMID: 31128712

93

Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions.

Lindberg K, Grozman V, Lindberg S, Onjukka E, Lax I, Lewensohn R, Wersäll P. Lindberg K, et al. Among authors: lax i. Acta Oncol. 2019 Aug;58(8):1178-1186. doi: 10.1080/0284186X.2019.1601255. Epub 2019 May 8. Acta Oncol. 2019. PMID: 31066326

94

Accuracy of the dose-shift approximation in estimating the delivered dose in SBRT of lung tumors considering setup errors and breathing motions.

Karlsson K, Lax I, Lindbäck E, Poludniowski G. Karlsson K, et al. Among authors: lax i. Acta Oncol. 2017 Sep;56(9):1189-1196. doi: 10.1080/0284186X.2017.1310395. Epub 2017 Apr 7. Acta Oncol. 2017. PMID: 28388257

95

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.

Buchli C, Martling A, Abani MA, Frödin JE, Bottai M, Lax I, Arver S, Holm T. Buchli C, et al. Among authors: lax i. Ann Surg. 2018 Feb;267(2):326-331. doi: 10.1097/SLA.0000000000002081. Ann Surg. 2018. PMID: 27849668 Clinical Trial.

96

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I. Nyman J, et al. Among authors: lax i. Radiother Oncol. 2016 Oct;121(1):1-8. doi: 10.1016/j.radonc.2016.08.015. Epub 2016 Sep 3. Radiother Oncol. 2016. PMID: 27600155 Clinical Trial.

97

Developmental and gender influences on executive function following concussion in youth hockey players.

Lax ID, Paniccia M, Agnihotri S, Reed N, Garmaise E, Azadbakhsh M, Ng J, Monette G, Wiseman-Hakes C, Taha T, Keightley M. Lax ID, et al. Brain Inj. 2015;29(12):1409-19. doi: 10.3109/02699052.2015.1043344. Epub 2015 Sep 11. Brain Inj. 2015. PMID: 26362811

98

Assessment of testicular dose during preoperative radiotherapy for rectal cancer.

Buchli C, Al Abani M, Ahlberg M, Holm T, Fokstuen T, Bottai M, Frödin JE, Lax I, Martling A. Buchli C, et al. Among authors: lax i. Acta Oncol. 2016;55(4):496-501. doi: 10.3109/0284186X.2015.1073349. Epub 2015 Sep 11. Acta Oncol. 2016. PMID: 26362484 Clinical Trial.

99

Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience.

Lindberg K, Nyman J, Riesenfeld Källskog V, Hoyer M, Lund JÅ, Lax I, Wersäll P, Karlsson K, Friesland S, Lewensohn R. Lindberg K, et al. Among authors: lax i. Acta Oncol. 2015;54(8):1096-104. doi: 10.3109/0284186X.2015.1020966. Epub 2015 Mar 27. Acta Oncol. 2015. PMID: 25813471 Clinical Trial.

100

Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.

Lindblom E, Antonovic L, Dasu A, Lax I, Wersäll P, Toma-Dasu I. Lindblom E, et al. Among authors: lax i. Radiat Oncol. 2014 Jun 30;9:149. doi: 10.1186/1748-717X-9-149. Radiat Oncol. 2014. PMID: 24974778 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

192 results

Search Page